Neumora Therapeutics (NASDAQ:NMRA) Rating Reiterated by William Blair

Neumora Therapeutics (NASDAQ:NMRA)‘s stock had its “outperform” rating reissued by stock analysts at William Blair in a note issued to investors on Friday, RTT News reports.

A number of other brokerages have also issued reports on NMRA. JPMorgan Chase & Co. boosted their price target on Neumora Therapeutics from $20.00 to $22.00 and gave the company an “overweight” rating in a report on Monday, March 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $31.00 price target on shares of Neumora Therapeutics in a report on Thursday, March 28th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.57.

Neumora Therapeutics Stock Down 3.2 %

NMRA opened at $13.56 on Friday. The stock’s 50 day moving average price is $16.14 and its 200-day moving average price is $14.22. Neumora Therapeutics has a one year low of $9.35 and a one year high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Thursday, March 7th. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.05. Equities analysts forecast that Neumora Therapeutics will post -1.48 earnings per share for the current year.

Institutional Trading of Neumora Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Neumora Therapeutics by 661.9% during the fourth quarter. Vanguard Group Inc. now owns 380,954 shares of the company’s stock worth $6,495,000 after buying an additional 330,954 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Neumora Therapeutics by 704.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 592,422 shares of the company’s stock worth $10,101,000 after buying an additional 518,822 shares during the period. American International Group Inc. purchased a new stake in Neumora Therapeutics during the fourth quarter worth $126,000. GSA Capital Partners LLP purchased a new stake in Neumora Therapeutics during the fourth quarter worth $799,000. Finally, Virtus ETF Advisers LLC purchased a new stake in Neumora Therapeutics during the fourth quarter worth $108,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.